-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7

Benzinga·05/14/2026 14:24:04
Listen to the news
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $8 to $7.